CGT
SUPN icon

Capital Guardian Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

Capital Guardian Trust’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-190
Closed -$3K – 773
2016
Q1 		$3K Buy
+190
New +$2.48K ﹤0.01% 732

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Guardian Trust's SUPN Position: Q2 2016 in Review

Capital Guardian Trust sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 190 shares — an estimated $3K sold.

Capital Guardian Trust first reported a position in SUPN in Q1 2016 and held it in 1 quarter. The position peaked at $3K in Q1 2016. 214 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

  • Capital Guardian Trust reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Capital Guardian Trust sold 190 Supernus Pharmaceuticals shares in Q2 2016, an estimated $3K.
  • Capital Guardian Trust first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Capital Guardian Trust's Supernus Pharmaceuticals position peaked at $3K in Q1 2016.
  • 214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Capital Guardian Trust's 13F filing for Q2 2016, filed 15 Aug 2016.